Article
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
CNS drugs - 1 Jun 2017
Kocis Petr, Tolar Martin, Yu Jeremy, Sinko William, Ray Soumya, Blennow Kaj, Fillit Howard, Hey John A
Abstract excerpt
BACKGROUND: Amyloid beta (Aβ) oligomers play a critical role in the pathogenesis of Alzheimer's disease (AD) and represent a promising target for drug development. Tramiprosate is a small-molecule Aβ anti-aggregation agent that was evaluated in phase III clinical trials for AD but did not meet the primary efficacy endpoints; however, a pre-specified subgroup analysis revealed robust, sustained, and clinically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.